Intensifying Lipid-Lowering Therapy in High-Risk Patients

Current Risk Assessment and Target LDL-C

The American College of Cardiology recommends a target LDL-C of <55 mg/dL for very high-risk patients, with at least a 50% reduction from baseline for patients with established coronary disease 1, 2, 3
Patients with established atherosclerotic cardiovascular disease (ASCVD) are considered very high-risk, and their current LDL-C level of 105 mg/dL represents nearly double the recommended target, creating substantial residual cardiovascular risk 1, 3

The American College of Cardiology suggests that bempedoic acid is specifically indicated for statin-intolerant patients, demonstrating a 13% reduction in major adverse cardiovascular events (MACE) in the CLEAR Outcomes trial 1, 4
Bempedoic acid provides a 15-25% additional LDL-C reduction with minimal muscle-related adverse effects because it is activated only in the liver, not in skeletal muscle 1, 4

The American College of Cardiology recommends initiating bempedoic acid 180 mg once daily in addition to current ezetimibe 10 mg, which can lower LDL-C by approximately 35% total 1, 4
Monitoring liver function tests at baseline and periodically is necessary, as bempedoic acid can cause elevations in hepatic enzymes 1, 2
Monitoring uric acid levels is also necessary, as bempedoic acid can increase uric acid and may precipitate gout in susceptible patients 1

The American College of Cardiology advises against delaying intensification of lipid therapy, as therapeutic inertia is a major contributor to suboptimal outcomes in high-risk patients 3, 6
The American College of Cardiology recommends not attempting statin rechallenge without addressing the pain issue first, as this patient has already failed statin therapy due to pain 1, 4
The American College of Cardiology suggests not accepting LDL-C of 105 mg/dL as adequate, as this level leaves substantial residual cardiovascular risk in a patient with established coronary disease 1, 3